A Phase 1 interventional study of JNJ-64565111 and Placebo in Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development, LLC. Terminated at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Johnson & Johnson.
Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, this one is the 48th largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 1, and was the 55th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 115 across the 54 interventional studies, 13,252 across the 8 observational. Of the 62 that completed or were terminated, 21 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
Drug: JNJ-64565111 · Drug: Placebo
Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
Drug: JNJ-64565111 · Drug: Placebo
Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
Drug: JNJ-64565111 · Drug: Placebo
Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
Drug: JNJ-64565111 · Drug: Placebo
Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: Up to Day 72
Number of Participants With Incidence of Anti-JNJ-64565111 Antibodies as Measure of Immunogenicity
Time frame: Up to Day 72
Change From Baseline in Body Weight
Time frame: Baseline, up to Day 72
Maximum Observed Plasma Concentration (Cmax)
Maximum observed plasma concentration (Cmax) will be assessed after first dose and last dose.
Time frame: Up to Day 72
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax defined as actual sampling time to reach maximum observed analyte concentration will be assessed after first dose and last dose.
Time frame: Up to Day 72
Area Under Concentration from time zero to the last quantifiable concentration AUC(0-last)
AUC from time zero to the last quantifiable concentration will be assessed after first dose and after last dose.
Time frame: Up to Day 72
Area Under Curve over the dosing interval AUC(0-tau)
The AUC \[0-tau\] is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption. AUC \[0-tau\] will be assessed after first dose and last dose.
Time frame: Up to Day 72
Elimination Half-Life (t1/2)
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. t1/2 will be assessed after first dose and last dose.
Time frame: Up to Day 72
Apparent Clearance (CL/F)
The Oral Clearance (CL/F) is the clearance based on oral bioavailability. CL/F will be assessed after first dose and last dose.
Time frame: Up to Day 72
Apparent Volume of Distribution (V/F)
Apparent volume of distribution will be assessed after first dose and last dose.
Time frame: Up to Day 72
Terminal Rate Constant (K)
Terminal rate constant will be assessed after first dose and last dose.
Time frame: Up to Day 72
Average concentration over the dosing interval at steady state (Caverage,ss)
The average concentration over the dosing interval at steady state, calculated as AUC(0-tau)/tau and will be assessed after last dose.
Time frame: Up to Day 72
Minimum Observed Plasma Concentration (Cmin)
The Cmin is the minimum observed plasma concentration over the dosing interval at steady state. Cmin will be assessed after last dose.
Time frame: Up to Day 72
Area Under Curve from time zero extrapolated to infinity AUC(0-inf)
AUC from time zero extrapolated to infinity will be assessed after last dose.
Time frame: Up to Day 72
Accumulation Ratio
Accumulation ratio calculated as AUC(0-tau), Day 22 / AUC(0-tau), Day 1 will be assessed after last dose.
Time frame: Up to Day 72
Change From Baseline in Blood Pressure
Time frame: Baseline, up to Day 72
Change From Baseline in Heart Rate
Time frame: Baseline, up to Day 72
Change From Baseline for 24-hour Mean Plasma Glucose
Mean plasma glucose defined as the total and/or incremental area under the concentration (AUC) time curve over 0 to 24 hours, divided by 24.
Time frame: Baseline, Day 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Time frame: Baseline, up to Day 72
Change From Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, up to Day 72
Change From Baseline on Fasting Lipids
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides and free fatty acids will be reported.
Time frame: Baseline, up to Day 72
Change From Baseline in Insulin Secretion
Time frame: Baseline, Day 26
Change From Baseline in Insulin Sensitivity
Time frame: Baseline, Day 26
Change From Baseline for C-peptide
Time frame: Baseline, Day 26
Change From Baseline for Glucagon
Time frame: Baseline, Day 26
Ran from Jul 2016 to primary completion in Nov 2016, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Janssen Research & Development, LLC →